Asset Details
Do you wish to reserve the book?
Top Italian public health official faces allegation of failing to disclose pharma links
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Top Italian public health official faces allegation of failing to disclose pharma links
Do you wish to request the book?
Top Italian public health official faces allegation of failing to disclose pharma links
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Top Italian public health official faces allegation of failing to disclose pharma links
2018
Overview
The country’s leading consumer rights group, Codacons, this week published what it said were all the relations between Walter Ricciardi, head of the National Institute of Health (Istituto Superiore di Sanita, ISS) and the drug industry.1 The group said that Ricciardi should be investigated for activities including the receipt of €4000 (£3600; $4500) for speaking to Pfizer staff in 2017, his involvement in a project sponsored by Pfizer and Janssen-Silage with the medicine faculty of Milan’s Catholic University of the Sacred Heart, a €400 sponsorship payment from GlaxoSmithKline in November 2017, and his role as “scientific director” in an Abbvie project that involved a payment of €58 250 to the Milan university. In 2015 The BMJ reported how one Italian vaccine expert who criticised plans to expand Italy’s national vaccination programme was threatened with legal action by government medical officers.2 Vittorio Demicheli, of the Cochrane Collaboration Vaccines Field, said then that plans to introduce vaccines against human papillomavirus for males, rotavirus for infants, and Herpes zoster and pneumococcal polysaccharide jabs for elderly people were too costly or ill advised, and he questioned the motives behind the new programme, which was written by a panel that included Ricciardi. The rate of measles, mumps, and rubella vaccine coverage in Italy fell from 90.5% in 2010 to 87.2% in 2016,4 although there is some evidence of a rise in uptake of 2.9% since then in some regions.5 Italy currently accounts for roughly a third of all measles cases reported by countries in the European Economic Area. 1 Day M. Italian expert questions need for expanded vaccination schedule.
Publisher
BMJ Publishing Group LTD
Subject
